Teleflex Announces Clinical and Real-World Evidence Studies and Physician Educational Opportunities to Be Highlighted at the 2025 American Urological Association (AUA) Annual Meeting
Teleflex (NYSE:TFX) has announced multiple clinical studies and educational sessions to be presented at the 2025 American Urological Association Annual Meeting in Las Vegas from April 26-29, 2025.
The presentations will focus on clinical and real-world evidence supporting innovations in benign prostatic hyperplasia (BPH) treatment and rectal spacing for prostate cancer radiation treatment. Key studies include the CLEAR Randomized Controlled Trial comparing UroLift™ PUL versus Rezum WVTT, the IMPACT trial evaluating UroLift™ PUL versus medication, and research on the safety of stabilized hyaluronic acid as a rectal spacer.
The company will host several educational events, including a Semi-Live Barrigel Case Review, an APP educational breakfast on efficient urology practice, and a Prostate Health Symposium at Allegiant Stadium. Daily presentations will also take place at Teleflex booth 1401, featuring discussions on both the Barrigel™ rectal spacer and UroLift™ System.
Teleflex (NYSE:TFX) ha annunciato numerosi studi clinici e sessioni educative che saranno presentati al Meeting Annuale 2025 dell'American Urological Association a Las Vegas dal 26 al 29 aprile 2025.
Le presentazioni si concentreranno su evidenze cliniche e real-world a supporto delle innovazioni nel trattamento dell'iperplasia prostatica benigna (IPB) e nell'uso di distanziatori rettali per la radioterapia del cancro alla prostata. Gli studi principali includono il trial randomizzato CLEAR che confronta UroLift™ PUL con Rezum WVTT, lo studio IMPACT che valuta UroLift™ PUL rispetto alla terapia farmacologica, e ricerche sulla sicurezza dell'acido ialuronico stabilizzato come distanziatore rettale.
L'azienda organizzerà diversi eventi formativi, tra cui una revisione semi-live di casi Barrigel, una colazione educativa per APP focalizzata sull'efficienza nella pratica urologica, e un Simposio sulla salute della prostata all'Allegiant Stadium. Ogni giorno si terranno inoltre presentazioni presso lo stand Teleflex 1401, con approfondimenti sia sul distanziatore rettale Barrigel™ sia sul sistema UroLift™.
Teleflex (NYSE:TFX) ha anunciado múltiples estudios clínicos y sesiones educativas que se presentarán en la Reunión Anual 2025 de la American Urological Association en Las Vegas, del 26 al 29 de abril de 2025.
Las presentaciones se centrarán en evidencias clínicas y del mundo real que respaldan innovaciones en el tratamiento de la hiperplasia prostática benigna (HPB) y en el uso de separadores rectales para el tratamiento de radiación del cáncer de próstata. Los estudios clave incluyen el ensayo controlado aleatorizado CLEAR que compara UroLift™ PUL frente a Rezum WVTT, el ensayo IMPACT que evalúa UroLift™ PUL frente a medicación, y la investigación sobre la seguridad del ácido hialurónico estabilizado como separador rectal.
La compañía organizará varios eventos educativos, incluyendo una revisión de casos semi-en vivo de Barrigel, un desayuno educativo para APP sobre la práctica eficiente en urología, y un Simposio de Salud Prostática en el Allegiant Stadium. También se realizarán presentaciones diarias en el stand de Teleflex 1401, con discusiones sobre el separador rectal Barrigel™ y el sistema UroLift™.
Teleflex (NYSE:TFX)는 2025년 4월 26일부터 29일까지 라스베이거스에서 열리는 2025 미국 비뇨기과학회 연례회의에서 발표될 여러 임상 연구 및 교육 세션을 발표했습니다.
발표 내용은 양성 전립선 비대증(BPH) 치료 및 전립선암 방사선 치료를 위한 직장 간격 조절에 대한 임상 및 실제 증거에 중점을 둡니다. 주요 연구로는 UroLift™ PUL과 Rezum WVTT를 비교한 CLEAR 무작위 대조 시험, UroLift™ PUL과 약물 치료를 평가한 IMPACT 시험, 그리고 직장 간격 조절제로서 안정화 히알루론산의 안전성 연구가 포함됩니다.
회사는 Barrigel 반실시간 사례 검토, 효율적인 비뇨기과 진료를 위한 APP 교육용 아침 식사, Allegiant 경기장에서의 전립선 건강 심포지엄 등 여러 교육 행사를 주최할 예정입니다. 또한 Teleflex 부스 1401에서 매일 Barrigel™ 직장 간격 조절기와 UroLift™ 시스템에 대한 발표가 진행됩니다.
Teleflex (NYSE:TFX) a annoncé plusieurs études cliniques et sessions éducatives qui seront présentées lors du Congrès annuel 2025 de l'American Urological Association à Las Vegas, du 26 au 29 avril 2025.
Les présentations porteront sur des preuves cliniques et issues du monde réel soutenant les innovations dans le traitement de l’hyperplasie bénigne de la prostate (HBP) et l’utilisation d’espaces rectaux pour la radiothérapie du cancer de la prostate. Les études clés comprennent l’essai contrôlé randomisé CLEAR comparant UroLift™ PUL et Rezum WVTT, l’essai IMPACT évaluant UroLift™ PUL versus traitement médicamenteux, ainsi que des recherches sur la sécurité de l’acide hyaluronique stabilisé comme espaceur rectal.
L’entreprise organisera plusieurs événements éducatifs, dont une revue de cas semi-live Barrigel, un petit-déjeuner éducatif pour APP sur la pratique urologique efficace, et un symposium sur la santé de la prostate au Allegiant Stadium. Des présentations quotidiennes auront également lieu au stand Teleflex 1401, avec des discussions sur l’espaceur rectal Barrigel™ et le système UroLift™.
Teleflex (NYSE:TFX) hat mehrere klinische Studien und Schulungssitzungen angekündigt, die auf dem Jahrestreffen 2025 der American Urological Association in Las Vegas vom 26. bis 29. April 2025 vorgestellt werden.
Die Präsentationen konzentrieren sich auf klinische und realweltliche Evidenz, die Innovationen in der Behandlung der benignen Prostatahyperplasie (BPH) und bei der Verwendung von rektalen Abständen für die Strahlenbehandlung von Prostatakrebs unterstützt. Zu den wichtigsten Studien gehören die randomisierte kontrollierte CLEAR-Studie, die UroLift™ PUL mit Rezum WVTT vergleicht, die IMPACT-Studie, die UroLift™ PUL mit medikamentöser Behandlung evaluiert, sowie Untersuchungen zur Sicherheit von stabilisiertem Hyaluronsäure als rektalem Abstandshalter.
Das Unternehmen wird mehrere Bildungsveranstaltungen ausrichten, darunter eine halb-live Barrigel-Fallbesprechung, ein APP-Bildungsfrühstück zur effizienten urologischen Praxis und ein Prostatagesundheits-Symposium im Allegiant Stadium. Tägliche Präsentationen finden zudem am Teleflex-Stand 1401 statt, mit Diskussionen sowohl über den Barrigel™ rektalen Abstandshalter als auch das UroLift™ System.
- None.
- None.
Experienced Urologists to Present Latest Findings and Host Multiple Educational Sessions
WAYNE, Pa., April 24, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the presentation of several clinical studies at the 2025 American Urological Association Annual Meeting, which is being held in Las Vegas from April 26 - 29, 2025. These studies contribute to the expanding body of clinical and real-world evidence supporting innovations in benign prostatic hyperplasia (BPH) treatment and rectal spacing to protect tissue during radiation treatment for prostate cancer.
“Understanding how leading treatment options perform—both in rigorous clinical trials and in everyday practice—is essential to empowering the future of healthcare for patients,” said Travis Gay, president and general manager of Teleflex Interventional Urology. “At Teleflex, we are deeply committed to advancing evidence-based innovation. Through ongoing real-world clinical trial research, we continue to support the safe and effective use of the UroLift™ System and Barrigel™ rectal spacer, helping physicians enhance outcomes and quality of life for patients.”
Clinical Study Presentations:
- Results from the CLEAR Randomized Controlled Trial (RCT) Suggest Factors Corresponding to Early Patient Satisfaction Are Better Following UroLift PUL Versus Rezum WVTT†– Moderated Poster Presentation; Saturday, April 26, 3:30–5:30 pm in Casanova, Room 505
The CLEAR randomized controlled trial compares patient outcomes between UroLift™ PUL and Rezum WVTT.1 The presentation is being moderated by Dr. Bilal Chughtai*, urologist, Northwell Health, Garden City, N.Y. - Patients Dissatisfied with BPH Medication in the IMPACT RCT Demonstrate Worse Patient Experience and Sleep Quality Before Crossing Over to UroLift PUL.† – Podium Presentation; Saturday April 26, 1:00–3:00 pm in Galileo, Room 901
The IMPACT randomized controlled trial evaluates safety, efficacy, and patient experience in BPH patients treated with UroLift™ PUL versus medication (tamsulosin).2 The presentation is presented by Dr. Dean Elterman*, associate professor of urology, the University of Toronto. - Using the American Urological Association Quality Registry (AQUA) BPH Dataset to Assess Early Symptom Improvement after Treatment. Moderated Poster Presentation; Saturday, April 26, 3:30–5:30 Casanova 505.
An analysis utilizing the AQUA database moderated by Dr. Claus Roehrborn*, Professor and Chairman, Department of Urology, University of Texas Southwestern Medical Center, Dallas, Tex.3 - Safety of Stabilized Hyaluronic Acid (sHA) as a Rectal Spacer: Low Risk of Rectal Wall Infiltration (RWI) and Reversibility – Poster Session; Tuesday, April 29, 9:30 – 11:30 am in Marco Polo 703
A research team in Australia, led by Professor Dr. Michael Chao*, a radiation oncologist at the Olivia Newton John Cancer Wellness & Research Centre in Victoria, Australia, conducted a study on the safety of sHA rectal spacers in cases of RWI.4
Teleflex and AUA are also hosting multiple educational events:
“Semi-Live Barrigel Case Review and Discussion” on Saturday, April 26, 2:35 – 3:05 pm in the Venetian Ballroom. In this AUA event, Dr. Varun Sundaram*, a urologist with Urology Austin, in Tex., will present insights from a recent Barrigel™ rectal spacer case, offering commentary and technical guidance on spacing procedures. This is an AUA event for which Teleflex provided funding.
The second annual advanced practice provider (APP) educational breakfast, “Engaging the APP in an Efficient Urology Practice” on Sunday, April 27, 6:45 – 8:00 am in Palazzo Ballroom B. Dr. Gregg Eure* with University of Virginia Health, Culpeper, Va.; Janelle Bunce*, PA-C with Advanced Urology Institute in Naples, Fla.; and Jamie Giovanelli*, PA-C with Urology of Virginia in Suffolk, Va. will discuss how to empower APPs to support the patient care pathway for patients with BPH and lower urinary tract symptoms. The discussion will center on the role of the APP in minimally invasive surgical therapies, including ultrasound gland sizing, if within scope of practice; in-office post procedure observations; and return post-op visits.
Prostate Health Symposium, “Transforming Quality of Life Through Personalized Prostate Care” on Sunday, April 27, 5:15 – 8:00 pm at Allegiant Stadium. In this first-ever combined UroLift™ System and Barrigel™ rectal spacer forum, a panel of experienced physicians—Dr. Zachary Klaassen*, urologic oncologist with Augusta University Medical Center/Georgia Cancer Center; Dr. Olubayo Tojuola*, urologist with Memorial Hermann Hospital at Houston, Tex.; and Dr. Ned Ruhotina*, a urologist with Associated Medical Professionals in Syracuse, N.Y.—will share real-world techniques for optimizing prostate radiation therapy with Barrigel™ rectal spacer and enhancing BPH outcomes with the UroLift™ System.
In addition to these events, presentations will take place daily at Teleflex booth 1401 as follows:
Presentations focused on Barrigel™ rectal spacer:
Zachary Klaassen, MD, MSC* – Getting Started with Barrigel Rectal Spacer
Saturday, April 26, 3:00 pm
Anne Hong, MD* – RWIs & Reversibility
Sunday, April 27, 11:00 am
Presentations focused on UroLift™ System:
David Sussman, DO, FACOS* – The Importance of Implant Density & Updates Regarding Recent Publications
Saturday, April 26, 1:30 pm
Silvia Secco, MD* – UroLift System: Surgical Experience & Competitive Advantages
Sunday, April 27, 1:30 pm
For more information about the UroLift System, visit www.UroLift.com, and for more information about Barrigel Rectal Spacer, visit www.Barrigel.com.
About the UroLift™ System
The UroLift™ System is a minimally invasive treatment for lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). It is indicated for the treatment of symptoms of an enlarged prostate up to 100cc in men 45 years or older (50 years outside U.S.). The UroLift™ System permanent implants, which can be delivered during an outpatient procedure,5 relieve prostate obstruction without heating, cutting, destruction of, or removing prostate tissue. The UroLift™ System can be used to treat a broad spectrum of anatomies, including obstructive median lobe.6 It is the only leading BPH procedure shown to not cause new onset, sustained erectile or ejaculatory dysfunction.**7-8 A study conducted over 5 years showed a low retreatment rate of about 2
Caution: Federal (USA) law restricts this device to sale by or on the order of a physician.
About Barrigel™ Rectal Spacer
Barrigel™ rectal spacer is the first and only hyaluronic acid rectal spacer that separates the prostate from the rectum to protect the rectum during radiation therapy treatment for prostate cancer.12 Barrigel™ rectal spacer is made from Non-Animal Stabilized Hyaluronic Acid (NASHA).13
Hyaluronic acid is a substance naturally present in the human body and is highly biocompatible and fully absorbable. NASHA has a proven history of safety and efficacy in a wide variety of medical applications in men, women and children worldwide.14-15
Barrigel™ rectal spacer has been proven to significantly reduce unwanted side effects from prostate cancer radiation therapy12 and is cleared for rectal spacing in the United States, Australia, and Europe.16 Barrigel™ rectal spacer is indicated for prostate cancer patients with T1-T3b disease. For more information about Barrigel™ rectal spacer, please visit https://barrigel.com/hcp/barrigel-control-matters.
Barrigel™ Rectal Spacer Important Safety Information
Barrigel™ rectal spacer is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and, in creating this space, it is the intent of Barrigel™ rectal spacer to reduce the radiation dose delivered to the anterior rectum. Barrigel™ rectal spacer is composed of biodegradable material and maintains space for the entire course of prostate radiotherapy treatment and is intended to be absorbed by the patient’s body over time.
Barrigel™ rectal spacer should only be administered by qualified and properly trained physicians with experience in ultrasound guidance and injection techniques in the urogenital/pelvic area.
As with any medical treatment, there are some risks involved with the use of Barrigel™ rectal spacer. Potential complications associated with the use of Barrigel™ rectal spacer include, but are not limited to: pain associated with Barrigel™ rectal spacer injection; needle penetration of the bladder, prostate, rectal wall, rectum, or urethra; injection of Barrigel™ rectal spacer into the bladder, prostate, rectal wall, rectum, urethra, or intravascularly; local inflammatory reactions; infection; urinary retention; rectal mucosal damage, ulcers, necrosis; bleeding; constipation; and rectal urgency. More information on indications, contraindications, warnings and instructions for use can be found in the Instructions For Use at www.barrigel.com. Individual results may vary.
Caution: Federal (USA) law restricts this device to sale by or on the order of a physician.
About Teleflex Incorporated
As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.
Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.
At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management’s current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.
Teleflex, the Teleflex logo, Arrow, Barrigel, Deknatel, LMA, Pilling, QuikClot, Rüsch, UroLift, and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. All other trademarks are the property of their respective owners.
© 2025 Teleflex Incorporated. All rights reserved.
References
*Paid consultants of Teleflex.
**No instances of new, sustained erectile or ejaculatory dysfunction in the L.I.F.T. pivotal study
†Studies sponsored by Teleflex.
- Chughtai et al, AUA 2025. Results from the CLEAR Randomized Controlled Trial (RCT) Suggest Factors Corresponding to Early Patient Satisfaction Are Better Following UroLift PUL Versus Rezum WVTT. †
- Roehrborn et al, AUA 2025. Patients Dissatisfied with BPH Medication in the IMPACT RCT Demonstrate Worse Patient Experience and Sleep Quality Before Crossing Over to UroLift PUL.†
- Roehrborn. Using the American Urological Association Quality Registry (AQUA) BPH Dataset to Assess Early Symptom Improvement after Treatment. Poster presented at AUA; April 26, 2025. Las Vegas, NV.
- Chao et al, AUA 2025. Safety of Stabilized Hyaluronic Acid (sHA) as a Rectal Spacer: Low Risk of Rectal Wall Infiltration and Reversibility.
- Shore, Can J Urol 2014
- Rukstalis, Prostate Cancer and Prostatic Dis 2018
- AUA BPH Guidelines 2003, 2020
- McVary, Urology 2019
- Roehrborn, Can J Urol 2017
- Roehrborn, J Urol 2013
- Management estimate based on product sales as of June 2024. Data on file Teleflex Interventional Urology.
- Mariados NF, Orio PF III, King MT et al. JAMA Oncol (2023).
- Barrigel Injectable Gel Instructions for Use (2022).
- Svatos M, Chell E, Low DA, et al. Symmetry, separation, and stability: Physical properties for effective dosimetric space with a stabilized hyaluronic acid spacer. Med Phys. 2024; 1-15. https://doi.org/10.1002/mp.17292†
- Restylane® celebrates 25 years of natural-looking results with its signature line of hyaluronic acid fillers. 2021. Available at: https://www.prnewswire.com/news-releases/restylane-celebrates-25-years-of-natural-looking-results-with-its-signature-line-of-hyaluronic-acid-fillers-301388779.html. Accessed Sept 30, 2021.
- Data on file Teleflex. 2025.
Contacts:
Teleflex
Lawrence Keusch
Vice President, Investor Relations and Strategy Development
investor.relations@teleflex.com
610-948-2836
Media Contact:
Glenn Silver
Partner National Media Relations Specialist
glenn.silver@finnpartners.com
646-871-8485
MAC03077-01 Rev A
FAQ
What clinical trials will be presented at the 2025 AUA Meeting for Teleflex (TFX)?
When and where is Teleflex (TFX) presenting at the 2025 AUA Annual Meeting?
What educational events is Teleflex (TFX) hosting at the 2025 AUA Meeting?
What medical technologies will Teleflex (TFX) showcase at the 2025 AUA Meeting?
